There were 16 acquisitions of companies with small molecule drug assets in 2021 and one merger. Here is a more in-depth look into all of the lead small molecules acquired in 2021, including a review of:
- The lead molecules in each acquisition and their structural representations where disclosed
- The mechanism of action, stage, and indication of each lead molecule
- Relevant clinical data and rationale for each acquisition
request a trial
You don’t have time to read everything, but you can’t afford to fall behind.
Drug Hunter Premium is drug discovery, distilled, so you can quickly catch up and make informed decisions based on industry examples.
Get ahead now by requesting a trial.
